Paul Thomas, DO
Family Medicine · Center Point, IANPI 1427026749
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,919 of the $10,069 with a category attached, or 68.7%. 40 manufacturers reported payments, led by GSK at 33.3% of the total. Reporting peaked in 2020 at $3,697 and has fallen 67.4% since, to $1,203 in 2025. Among family medicine clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 468 payments — averaging $21.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- Pfizer$1K
- AstraZeneca$843
- Novo Nordisk$810
- AbbVie$709
- Lilly USA, LLC$495
- plus $3K from 34 others
What the payments were for
- Speaking & faculty fees$3,13531%
- Food & beverage$6,91969%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEXSERO$3,135
How this compares
$10,069 in reported general payments places this provider in the 95th percentile of 1,357 family medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 65 | $78,918 |
| MounjaroTirzepatide | 51 | $54,186 |
| EliquisApixaban | 61 | $50,279 |
| OzempicSemaglutide | 43 | $44,986 |
| TrulicityDulaglutide | 29 | $39,938 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $21,324 |
| JanuviaSitagliptin Phosphate | 30 | $21,312 |
| CreonLipase/Protease/Amylase | 12 | $13,533 |
| FarxigaDapagliflozin Propanediol | 11 | $11,802 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $7,175 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $5,987 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 151 | $4,381 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $4,308 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 224 | $3,802 |
| Atorvastatin Calcium | 522 | $3,405 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $495 | $94,12480 claims |
| Boehringer IngelheimJardiance | $486 | $78,91865 claims |
| PfizerEliquis | $1,314 | $50,27961 claims |
| Novo NordiskOzempic | $810 | $44,98643 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $3,351 | $27,31231 claims |
| MerckJanuvia | $201 | $21,31230 claims |
| AbbVieCreon | $709 | $13,53312 claims |
| AstraZenecaFarxiga | $843 | $11,80211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Center Point
- John LancasterCenter Point$6K
- Kirk PetersonHuxley$576K
- Nicholas GoetschWaterloo$525K
- Stephen HarrisonClinton$249K
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
- Leslie George PaulsenMuscatine$136K
- Dylan LoweDes Moines$105K
- Michael AbouassalyWest Burlington$88K
- Kevin DeregnierWinterset$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.